(Breast Cancer) Is Enhertu Effective for Brain Metastases?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Enhertu in HER2-Positive Breast Cancer with Brain Metastases — TUXEDO-1 Trial
On August 8, 2022, Rupert Bartsch and colleagues at the Medical University of Vienna published in the medical journal Nature Medicine the efficacy and safety results of the TUXEDO-1 Phase 2 trial evaluating Enhertu (trastuzumab deruxtecan) in patients with HER2-positive breast cancer with brain metastases.
Trial Design
The TUXEDO-1 Phase 2 trial administered Enhertu (5.4 mg/kg, 3-week cycles) to 15 patients with HER2-positive breast cancer with brain metastases who had either received no prior treatment or had prior treatment. The primary endpoint was intracranial response rate.
Patient characteristics: 60% of patients had developed brain metastases during disease progression on prior treatment; 14 female and 1 male patient; median age 69 years (range 30–76); ECOG performance status 0 in 40%; 12 patients had hormone receptor-positive disease.
Efficacy Results
- Intracranial response rate (primary endpoint): 73.3% (N=11/15)
- Complete response: 13.3% (N=2)
- Partial response: 60% (N=9)
- Stable disease: 20% (N=3)
- Median progression-free survival: 14 months
Conclusions
Based on the TUXEDO-1 trial results, Rupert Bartsch and colleagues concluded that Enhertu demonstrated a high intracranial response rate in patients with HER2-positive breast cancer with brain metastases.
Source: https://www.nature.com/articles/s41591-022-01935-8
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4